Danegaptide is under clinical development by Breye Therapeutics and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Danegaptide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Danegaptide overview

Danegaptide is under development for the treatment of diabetic retinopathy (DR) having macular edema and wet-age-related macular degeneration (AMD). The drug candidate is administered through oral route. It acts by targeting Connexin 43.

Breye Therapeutics overview

Breye Therapeutics is a biotechnology company that is engaged in developing novel oral therapies for retinal vascular diseases. Breye Therapeutics is headquartered in Copenhagen, Denmark.

For a complete picture of Danegaptide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.